CRPI pipeline of drug discovery
TA | Project | Regis- tration classi- fication | MOA | Indication | Description | Status |
Pre- clinical | IND | Clinical Trial | NDA |
I | II | III |
CNS | Rasa- giline trans- dermal patch | II | MAO-B inhibitor | Parkinson | (1)first sustained release formulation of Rasagiline (2) market exclusivity (3) once every 3 days,good compliance. | ![Innovation drug R&D Innovation drug R&D]() |
Tumor targeted therapy | 1 | 1 | Cellular stress responsive inhibitor | Triplene- gative breast cancer | First- in-class | ![Innovation drug R&D Innovation drug R&D]() |
2 | 1 | BTK inhibitor | B cell associated lymphoma | Me-better | ![Innovation drug R&D Innovation drug R&D]()
|
3 | 1 | PARP inhibitor | Ovarian cancer | Me-better | ![Innovation drug R&D Innovation drug R&D]() |
4 | 1 | Cell metabolic inhibitor | Cancer | First- in-class | ![Innovation drug R&D Innovation drug R&D]() |
Tumor immune therapy | 5 | 1 | Inhibitor containing PD-L1 | Caner | Small molecular, First- in-class | ![Innovation drug R&D Innovation drug R&D]() |
6 | 1 | Immune escape inhibitor | Caner | Small molecular, First- in-class | ![Innovation drug R&D Innovation drug R&D]() |